Table 2.
PLS3 and LCP1 polymorphisms and outcome in patients with stage II or III colon cancer by sex (Training set)
| Males | Females | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Median TTR, y (95% CI) | Prob ± SE* of 3-y recurrence | HR (95% CI) Univariate | HR (95% CI) Multivariate | N | Median TTR, y (95% CI) | Prob ± SE* of 3-y recurrence | HR (95% CI) Univariate | HR (95% CI) Multivariate | |
| PLS3 rs6643869 | ||||||||||
| G/G | 66 | 7.1 (3.5, 11.4+) | 0.33 ± 0.07 | 1 (Reference) | 1 (Reference) | 35 | 12.2+ (4.9, 12.2+) | 0.29 ± 0.08 | 1 (Reference) | 1 (Reference) |
| G/A | 27 | 5.2 (1.7, 10.7+) | 0.36 ± 0.10 | 1.38 (0.69, 2.75) | 1.48 (0.71, 3.08) | 33 | 9.4 (5.4, 9.4+) | 0.20 ± 0.08 | 0.89 (0.37, 2.14) | 0.75 (0.30, 1.92) |
| A/A | 0.35 | 0.30 | 14 | 1.7 (0.7, 5.9+) | 0.67 ± 0.13 | 2.69 (1.14, 6.35) | 1.96 (0.75, 5.13) | |||
| P† | 0.018 | 0.15 | ||||||||
| G/G or G/A | 68 | 9.4 (5.4, 12.2+) | 0.25 ± 0.06 | 1 (Reference) | 1 (Reference) | |||||
| A/A | 14 | 1.7 (0.7, 5.9+) | 0.67 ± 0.13 | 2.84 (1.32, 6.10) | 2.26 (0.97, 5.31) | |||||
| P† | 0.005 | 0.060 | ||||||||
| LCP rs11342 | ||||||||||
| G/G | 33 | 2.3 (1.5, 6.8+) | 0.52 ± 0.11 | 1 (Reference) | 1 (Reference) | 23 | 10.3+ | 0.23 ± 0.09 | 1 (Reference) | 1 (Reference) |
| G/T | 42 | 10.7 (5.2, 11.4+) | 0.17 ± 0.06 | 0.39 (0.17, 0.89) | 0.36 (0.14, 0.92) | 44 | 5.4 (1.8, 9.4+) | 0.40 ± 0.08 | 2.27 (0.86, 6.03) | 1.53 (0.50, 4.63) |
| T/T | 21 | 3.9 (1.4, 10.7+) | 0.41 ± 0.11 | 0.78 (0.34, 1.83) | 0.71 (0.29, 1.73) | 17 | 12.2+ (2.8, 12.2+) | 0.21 ± 0.11 | 1.00 (0.27, 3.71) | 0.68 (0.16, 2.85) |
| P† | 0.037 | 0.096 | 0.10 | 0.31 | ||||||
| G/T, T/T | 63 | 7.1 (4.9,11.4+) | 0.25 ± 0.06 | 0.51 (0.25,1.04) | 0.50 (0.23,1.10) | 61 | 5.7 (2.8,16.8+) | 0.35 ± 0.07 | 1.89 (0.72,4.93) | 1.29 (0.43,3.85) |
| P† | 0.042 | 0.085 | 0.19 | 0.65 | ||||||
| LCP rs4941543 | ||||||||||
| C/C | 75 | 10.7 (5.2, 11.4+) | 0.30 ± 0.06 | 1 (Reference) | 1 (Reference) | 66 | 9.4 (5.4, 16.8+) | 0.27 ± 0.06 | 1 (Reference) | 1 (Reference) |
| C/T‡ | 14 | 4.9 (1.0, 7.1+) | 0.35 ± 0.13 | 1.75 (0.77, 3.97) | 1.60 (0.64, 3.97) | 15 | 2.4 (0.7, 9.0+) | 0.52 ± 0.14 | 1.91 (0.81, 4.52) | 2.95 (1.10, 7.90) |
| T/T‡ | 1 | 0 | ||||||||
| P† | 0.17 | 0.32 | 0.13 | 0.031 | ||||||
*
Greenwood SE.
+
Estimates were not reached.
†
Based on log-rank test in the univariate analysis and based on Wald test within multivariate Cox proportional hazards model adjusting for stage and type of adjuvant therapy and stratified by race.
‡
In the dominant model.